Loading clinical trials...
Loading clinical trials...
A Real-World Registry Study to Evaluate Clinical Protection Outcomes Following Post-Exposure Prophylaxis With Zamerovimab and Mazorelvimab Injection in Combination With Rabies Vaccine in Pediatric With Category III Rabies Exposure
Conditions
Locations
6
China
Peking University First Hospital
Beijing, Beijing Municipality, China
Shenzhen second people's hospital
Shenzhen, Guangdong, China
The University of Hong Kong - Shenzhen Hospital
Shenzhen, Guangdong, China
Hunan Provincial People's Hospital
Changsha, Hunan, China
Affiliated Nanhua Hospital, University of South China
Hengyang, Hunan, China
Jiangxi Provincial Chest Hospital
Nanchang, Jiangxi, China
Start Date
August 2, 2025
Primary Completion Date
October 31, 2026
Completion Date
December 31, 2026
Last Updated
April 23, 2026
Lead Sponsor
Synermore Biologics (Suzhou) Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions